{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:00:47Z","timestamp":1790938847911,"version":"4.1.0"},"reference-count":28,"publisher":"Becaris Publishing Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Tafamidis and acoramidis are transthyretin stabilizers approved for the treatment of transthyretin amyloid cardiomyopathy. We compared the effectiveness of acoramidis versus tafamidis regarding all-cause mortality (ACM).\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    This study used a hybrid design to compare 42-month ACM with acoramidis versus tafamidis using trial emulation, calibration, and indirect treatment comparison. Two real-world cohorts of participants initiating tafamidis were identified from TriNetX (2019\u20132024) using observational analogues to emulate ATTR-ACT and ATTRibute-CM trial eligibility criteria and baseline characteristics. A calibration factor was derived by comparing 42-month ACM in the ATTR-ACT tafamidis arm with the ATTR-ACT emulation cohort to quantify the net effect of systematic differences between the populations. This factor was applied to the ATTRibute-CM emulation tafamidis cohort and compared with the ATTRibute-CM acoramidis arm. Using these values and corresponding variance, Monte Carlo simulation (MCS)-estimated medians and percentile-based 95% CIs were derived.\n                    <jats:bold>Results:<\/jats:bold>\n                    In the ATTRibute-CM emulation tafamidis cohort (n\u00a0=\u00a0617), 42-month ACM risk was 35.4% (95% CI: 29.6\u201342.0), and decreased to a MCS-estimated median of 31.2% (95% CI: 25.3\u201339.0) after application of the calibration factor (MCS-estimated median: 1.14 [95% CI: 0.91\u20131.43]). Comparison with 42-month ACM risk observed in the ATTRibute-CM acoramidis arm (24.0%, 95% CI: 20.0\u201328.7) yielded a relative risk of 0.78 (95% CI: 0.60\u20130.99), consistent with lower observed ACM risk in the acoramidis arm.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Acoramidis was linked to a lower estimated ACM risk in this emulated comparative analysis. These findings should be considered as hypothesis-generating, requiring confirmation in head-to-head studies.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0114","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:35:04Z","timestamp":1789378504000},"source":"Crossref","is-referenced-by-count":0,"title":["A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1196-3016","authenticated-orcid":false,"given":"Philippe","family":"Debonnaire","sequence":"first","affiliation":[{"name":"Department of Cardiology, AZ Sint-Jan Brugge, Bruges, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2634-4667","authenticated-orcid":false,"given":"Peter-Paul","family":"Zwetsloot","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Thoraxcenter, Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4358-5008","authenticated-orcid":false,"given":"Roman","family":"Pfister","sequence":"additional","affiliation":[{"name":"Faculty of Medicine &amp; University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0988-0599","authenticated-orcid":false,"given":"Pau","family":"Ll\u00e0cer","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7842-6202","authenticated-orcid":false,"given":"Alberto","family":"Cipriani","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic &amp; Vascular Sciences &amp; Public Health, Padova University Hospital, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2268-9422","authenticated-orcid":false,"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"},{"name":"Amyloidosis Research &amp; Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-5924","authenticated-orcid":false,"given":"Diana","family":"Bonderman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinic Favoriten, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2868-5211","authenticated-orcid":false,"given":"Christoph","family":"Ohlmeier","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9417-6773","authenticated-orcid":false,"given":"Thomas","family":"Evers","sequence":"additional","affiliation":[{"name":"Bayer AG, Wuppertal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6832-5900","authenticated-orcid":false,"given":"Richard","family":"Wyss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology &amp; Pharmacoeconomics, Department of Medicine, Brigham &amp; Women's Hospital &amp; Harvard Medical School, Boston, MA 02120, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-9898","authenticated-orcid":false,"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology &amp; Pharmacoeconomics, Department of Medicine, Brigham &amp; Women's Hospital &amp; Harvard Medical School, Boston, MA 02120, USA"},{"name":"Division of General Internal Medicine &amp; Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-1511","authenticated-orcid":false,"given":"Riddhi","family":"Doshi","sequence":"additional","affiliation":[{"name":"IQVIA Ltd., London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Beisel","sequence":"additional","affiliation":[{"name":"IQVIA Ltd., London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-7158","authenticated-orcid":false,"given":"Craig I","family":"Coleman","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT 06269, USA"},{"name":"Evidence-Based Practice Center, Hartford Hospital, Hartford, CT 06102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5970-6353","authenticated-orcid":false,"given":"Carlos","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Santa Cruz Hospital, Carnaxide, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-325X","authenticated-orcid":false,"given":"Tomas","family":"Ripoll-Vera","sequence":"additional","affiliation":[{"name":"Son Ll\u00e0tzer University Hospital &amp; IdISBa, Palma, Balearic Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg FL","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 2872\u20132891 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh TA","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 24, 4\u2013131 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"e_1_3_9_5_2","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 145, e895\u2013e1032 (2022).","journal-title":"Circulation"},{"key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review","volume":"79","author":"Rapezzi C","year":"2022","unstructured":"Rapezzi C, Aimo A, Serenelli M Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review. J. Am. Coll. Cardiol. 79, 1288\u20131303 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007\u20131016 (2018).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott P","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ. Heart Fail. 15, e008193 (2022).","journal-title":"Circ. Heart Fail."},{"key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore JD","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 390, 132\u2013142 (2024).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","volume":"151","author":"Judge DP","year":"2025","unstructured":"Judge DP, Gillmore JD, Alexander KM Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial. Circulation 151, 601\u2013611 (2025).","journal-title":"Circulation"},{"issue":"6","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"oeaf147","DOI":"10.1093\/ehjopen\/oeaf147","article-title":"Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis","volume":"5","author":"Aimo A","year":"2025","unstructured":"Aimo A, Castiglione V, Emdin M, Lorenzoni V, Vergaro G. Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis. Eur. Heart J. Open 5(6), oeaf147 (2025).","journal-title":"Eur. Heart J. Open"},{"key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40119-025-00422-8","article-title":"Transthyretin Kinetic Stabilizers for ATTR Amyloidosis","volume":"14","author":"Kelly JW","year":"2025","unstructured":"Kelly JW. Transthyretin Kinetic Stabilizers for ATTR Amyloidosis. Cardiol. Ther. 14, 327\u2013331 (2025).","journal-title":"Cardiol. Ther."},{"key":"e_1_3_9_13_2","unstructured":"RCT-DUPLICATE. RCT-DUPLICATE. (Accessed 15 January 2026). https:\/\/www.rct-duplicate.org\/"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3364"},{"key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials","volume":"329","author":"Wang SV","year":"2023","unstructured":"Wang SV, Schneeweiss S, Initiative R-D Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA 329, 1376\u20131385 (2023).","journal-title":"JAMA"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3621"},{"key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38, 200\u2013211 (2018).","journal-title":"Med. Decis. Making"},{"key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch JE","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15, 940\u2013947 (2012).","journal-title":"Value Health"},{"key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"31","author":"Garcia-Pavia P","year":"2025","unstructured":"Garcia-Pavia P, Kristen AV, Drachman B Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). J. Card. Fail. 31, 525\u2013533 (2025).","journal-title":"J. Card. Fail."},{"key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin PC","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34, 3661\u20133679 (2015).","journal-title":"Stat. Med."},{"key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot P","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 12, 9 (2012).","journal-title":"BMC Med. Res. Methodol."},{"key":"e_1_3_9_22_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0272989X8500500205","article-title":"Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach","volume":"5","author":"Doubilet P","year":"1985","unstructured":"Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med. Decis. Making 5, 157\u2013177 (1985).","journal-title":"Med. Decis. Making"},{"issue":"12","key":"e_1_3_9_23_2","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0735-1097(25)02138-2","article-title":"In participants treated with acoramidis, addition of concomitant tafamidis did not further increase serum TTR levels","volume":"85","author":"Maurer MS","year":"2025","unstructured":"Maurer MS, Cappelli F, Fontana M In participants treated with acoramidis, addition of concomitant tafamidis did not further increase serum TTR levels. J. Am. Coll. Cardiol. 85(Suppl. 12), 1654 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy","volume":"85","author":"Maurer MS","year":"2025","unstructured":"Maurer MS, Judge DP, Gillmore JD Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy. J. Am. Coll. Cardiol. 85, 1911\u20131923 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"e036755","DOI":"10.1161\/JAHA.124.036755","article-title":"Predictors of early death in patients with wild-type transthyretin cardiac amyloidosis","volume":"14","author":"Milani P","year":"2025","unstructured":"Milani P, Sanna GD, Mussinelli R Predictors of early death in patients with wild-type transthyretin cardiac amyloidosis. J. Am. Heart Assoc. 14, e036755 (2025).","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"8618","DOI":"10.1038\/s41467-026-74999-6","article-title":"Evaluating bias in target trial emulation for heart failure across statistical and deep learning methods","volume":"17","author":"Fan Z","year":"2026","unstructured":"Fan Z, Yang Q, Hu Y Evaluating bias in target trial emulation for heart failure across statistical and deep learning methods. Nat. Commun. 17(1), 8618 (2026).","journal-title":"Nat. Commun."},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2596820"},{"key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13023-023-02933-w","article-title":"Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases","volume":"18","author":"Damy T","year":"2023","unstructured":"Damy T, Bourel G, Slama M Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases. Orphanet J. Rare Dis. 18, 345 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ahj.2023.06.013","article-title":"Transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: Findings from GWTG-HF","volume":"265","author":"Peters AE","year":"2023","unstructured":"Peters AE, Solomon N, Chiswell K Transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: Findings from GWTG-HF. Am. Heart J. 265, 22\u201330 (2023).","journal-title":"Am. Heart J."},{"key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1038\/s41467-021-22876-9","article-title":"A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy","volume":"12","author":"Huda A","year":"2021","unstructured":"Huda A, Castano A, Niyogi A A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nat. Commun. 12, 2725 (2021).","journal-title":"Nat. Commun."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:43:44Z","timestamp":1790937824000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.57264\/cer-2026-0114"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0114","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"article-number":"e260114"}}